Notebook

ALZHEIMER'S VACCINE It's the classic vaccine approach: Get protection against a disease by training the body's immune system, using a bit of the disease itself, to respond to infection in force. Typically applied to infectious diseases such as smallpox or polio, immune system-boosting treatments have more recently been aimed at cancerous tumors. Now a recent paper suggests that Alzheimer's disease (AD) might be effectively treated by priming the immune system with a form of the damaging, neuro

Written byEugene Russo
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

ALZHEIMER'S VACCINE It's the classic vaccine approach: Get protection against a disease by training the body's immune system, using a bit of the disease itself, to respond to infection in force. Typically applied to infectious diseases such as smallpox or polio, immune system-boosting treatments have more recently been aimed at cancerous tumors. Now a recent paper suggests that Alzheimer's disease (AD) might be effectively treated by priming the immune system with a form of the damaging, neuron-suffocating amyloid plaques observed in the brains of AD patients. (D. Schenk et al., "Immunization with amyloid-ß attenuates Alzheimer-disease-like pathology in the PDAPP mouse," Nature, 400:173-7, July 8, 1999). Using a synthetic form of ß-amyloid (Aß), the peptide the plaques are composed of, researchers at Elan Pharmaceuticals of South San Francisco, Calif., showed that the synthetic peptide, called AN-1792, could both prevent and arrest plaque formation in a mouse model genetically engineered to exhibit ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies